Michael H. Davidson to Muscular Diseases
This is a "connection" page, showing publications Michael H. Davidson has written about Muscular Diseases.
Connection Strength
1.376
-
Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©. Patient. 2017 06; 10(3):321-334.
Score: 0.589
-
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf. 2004 Nov; 3(6):547-57.
Score: 0.246
-
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf. 2015 Jun; 14(6):935-55.
Score: 0.127
-
Overcoming toxicity and side-effects of lipid-lowering therapies. Best Pract Res Clin Endocrinol Metab. 2014 Jun; 28(3):439-52.
Score: 0.117
-
Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol. 2006 Apr 17; 97(8A):32C-43C.
Score: 0.067
-
Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006 Apr 17; 97(8A):61C-68C.
Score: 0.067
-
Clostridium septicum septicemia with identical metastatic myonecroses in a granulocytopenic patient. Infectious disease emergency. Am J Med. 1985 Aug; 79(2):256-8.
Score: 0.065
-
Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003 Mar 10; 163(5):553-64.
Score: 0.055
-
The mitochondrial tRNA(Leu)(UUR)) mutation in MELAS: a model for pathogenesis. Biochim Biophys Acta. 1992 Jul 17; 1101(2):206-9.
Score: 0.026
-
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006 Apr 17; 97(8A):89C-94C.
Score: 0.017